Clinical Trial Update: Bevacizumab in Extensive Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Updates on a clinical trial of bevacizumab in extensive small cell lung cancer, covering Phase 2 and Phase 3 results; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Small Cell Lung Cancer | Phase 2, Phase 3 | Status: COMPLETED